Arbutus Biopharma Logo
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
June 05, 2024 02:30 ET | Arbutus Biopharma Corporation
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were...
New data presented at AACR Annual Meeting demonstrates significantly enhanced anti-solid tumor effects of T cells co-expressing an optimal affinity TCR targeting NY-ESO-1 and a PD1-41BB co-stimulatory switch receptor (MDG1015)
April 18, 2023 09:30 ET | Medigene AG
Martinsried/Munich, April 18, 2023, Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023
April 18, 2023 09:00 ET | invIOs GmbH
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver...
Canon imagePROGRAF TC-20M
Canon U.S.A. Introduces Industry’s First Sub-$1,000, 24-Inch Large-Format Printer with a Built-in Flatbed Scanner, Ideal for Schools, Shop Owners & More
April 11, 2023 09:00 ET | Canon U.S.A., Inc.
Melville, NY, April 11, 2023 (GLOBE NEWSWIRE) -- Canon U.S.A., Inc., a leader in digital imaging solutions, today announced the imagePROGRAF TC-20M, a new large-format, multifunction, 4-color...
Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting
March 16, 2023 05:00 ET | Medigene AG
Martinsried/Munich, March 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Arbutus Biopharma Logo
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
November 01, 2022 16:01 ET | Arbutus Biopharma Corporation
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in...
Arbutus Biopharma Logo
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
October 31, 2022 16:02 ET | Arbutus Biopharma Corporation
Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Friday, November 4, 2022 WARMINSTER, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma...
Photo 1
Healthy Extracts New Clinical Study Highlights UBN RELIEF Naturally Alleviates Migraine Symptoms
June 08, 2022 08:31 ET | Healthy Extracts Inc.
LAS VEGAS, June 08, 2022 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, announced a poster...
aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting
March 11, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Educational Posters Available to Help Prevent the Spread of COVID-19
July 16, 2020 09:07 ET | NSF International
ANN ARBOR, Mich., U.S., July 16, 2020 (GLOBE NEWSWIRE) -- Global public health organization NSF International is offering small businesses, community centers, apartment complexes and other...